Reversal by phenytoin of carbamazepine-induced water intoxication: a pharmacokinetic interaction

E PERUCCA AND A RICHENS

From the Clinical Pharmacology Unit, University Department of Clinical Neurology, The National Hospital, London

SUMMARY The hypothesis that phenytoin may antagonise the antidiuretic effect of carbamazepine has been examined by comparing the free water clearance response to a standard water load in 36 patients stabilised on different drug regimes. The diuretic response to the water load was significantly greater in patients receiving chronic treatment with carbamazepine and phenytoin in combination than in matched control subjects receiving carbamazepine as a single drug. Acute administration of phenytoin (1,100 mg), however, had no significant influence on carbamazepine-induced antidiuresis. Evidence is presented that reversal of the antidiuretic effect of carbamazepine by chronic phenytoin administration is secondary to a marked reduction of the serum carbamazepine concentration during combined therapy. These results suggest that the risk of developing water intoxication is greater in patients receiving carbamazepine alone than in those receiving phenytoin in combination. Since the antidiuretic effect is correlated with the serum carbamazepine concentration rather than with the prescribed daily dose, monitoring the serum level of the drug is likely to provide the best rational approach to the prevention of excessive water retention.

Carbamazepine has antidiuretic properties which have been shown to be positively correlated with the concentration of the drug in serum. Excessive water retention is relatively common at serum concentration values close to the upper limit of the therapeutic range (12 to 42 μmol/l) and may be troublesome in some patients, particularly those receiving the drug for the treatment of epilepsy and trigeminal neuralgia. Interestingly, water intoxication appears to be more common in patients treated with carbamazepine alone than in those receiving phenytoin in combination and reversal of carbamazepine-induced antidiuresis by phenytoin has been recently described in one patient. Although in the latter report the mechanism of the interaction was assumed to be pharmacodynamic, that is, related to the inhibitory action of phenytoin on the release of antidiuretic hormone (ADH) from the posterior pituitary, there are no experimental data to support this hypothesis. We now report the results of a study in which this interaction and the mechanisms involved have been investigated in patients treated with carbamazepine, alone or in combination with phenytoin.

Patients and methods

Thirty-six epileptic patients of either sex, aged 20 to 57 years, and eleven drug-free normal control subjects were studied. Most patients were resident at the Chalfont Centre for Epilepsy, with the exception of five patients who attended the Outpatients’ Department of the National Hospital, Queen Square. All were stabilised on chronic treatment with carbamazepine alone or in combination with phenytoin; patients on other drugs were excluded from the study. All subjects had a normal plasma sodium and osmolality prior to the study. Subjects were assigned to different groups according to drug treatment (table). Age, sex and weight distribution were similar for each group. The antidiuretic effect of carbamazepine was assessed quantitatively by measuring the free water clearance in response to a standard water load (20 ml/Kg up to a maximum of 1600 ml) in each subject. Details of the experimental procedure have been described elsewhere. Serum and urine osmolality were determined by means
of an Advanced DigiMatic Osmeter, Model 3DII (Advanced Instruments Inc., Needham Heights, MA). The serum concentration of carbamazepine and phenytoin was determined by enzyme-immuno assay (EMIT) in samples collected immediately before and after the water load test (the concentrations reported represent the mean of these two values).

Results

Effect of phenytoin in patients matched for carbamazepine dose

The effect of chronic administration of phenytoin on carbamazepine-induced antidiuresis was examined by comparing the free water clearance response to a standard water load in six patients stabilised on carbamazepine alone (dose range 800 to 1800 mg/day) and in six matched subjects receiving chronic treatment with identical carbamazepine doses in combination with phenytoin. As illustrated in fig 1B, the diuretic response was found to be markedly impaired in patients treated with carbamazepine alone but the same was not true in the case of patients receiving phenytoin in combination. In the latter group, the fraction of the water load excreted during the test was found to be twice as high as in patients treated with carbamazepine alone (p<0.05) and, although lower, did not differ significantly from that observed in drug-free normal control subjects (table). In particular, only one of the phenytoin-treated patients had an abnormal diuretic response (defined as a urinary output below 60% of intake), while five out of the six patients included on the monotherapy group had abnormal responses. When steady state serum carbamazepine levels in the two groups were compared, however, a marked difference was found, patients on combination therapy showing significantly lower levels that patients treated with carbamazepine alone.

It is evident from fig 2 that the reduction in the antidiuretic effect of carbamazepine in the presence of phenytoin was associated with
markedly lower serum carbamazepine levels in patients receiving combination therapy.

**Effect of phenytoin in patients matched for serum carbamazepine concentration**

In order to ascertain whether the increased diuretic response in phenytoin-treated patients could be entirely accounted for by the lower serum carbamazepine levels in this group, water load tests were performed in six patients on carbamazepine alone and in six matched control subjects showing equivalent serum carbamazepine concentration but receiving phenytoin in combination. The diuretic response was found to be impaired to a similar extent in both groups (fig 1C and table). The dose of carbamazepine required to produce equivalent serum carbamazepine levels was significantly higher in patients receiving phenytoin, compared with patients treated with carbamazepine alone. As these findings further suggested that the inhibition of the antidiuretic effect of carbamazepine by phenytoin was secondary to a decrease of serum carbamazepine levels during phenytoin therapy, a within-subjects study was undertaken in which the effect of acute phenytoin administration was examined in patients receiving chronic treatment with carbamazepine alone. This would not be expected to lower carbamazepine levels to any appreciable extent.

**Effect of acute phenytoin administration**

Seven patients stabilised on carbamazepine alone (dose range 800 to 1800 mg/day) were included in this study. The diuretic response to a standard water load was determined in each patient on two different occasions separated by one week: 1) during regular treatment with carbamazepine alone and 2) following acute administration of phenytoin (1100 mg orally given in three doses of 500 mg, 400 mg and 200 mg at 24, 12 and 0·5 hrs prior to water loading respectively). The carbamazepine dose was maintained unchanged throughout the study and the sequence of testing was randomised.

As illustrated in fig 1D and the table, the excretion of water was markedly impaired in six patients. Acute administration of phenytoin had no significant influence on the diuretic response, which was only marginally greater than in the presence of carbamazepine alone. In six out of seven patients, the serum carbamazepine concentration fell slightly but significantly (p<0·05) after acute phenytoin administration, as compared to the values found during treatment with carbamazepine alone. In only one patient did the diuretic response reverse from abnormal (24% of water load excreted) to normal (70%) in the presence of phenytoin: the effect, however, was accompanied by a reduction in the serum carbamazepine concentration from 36 μmol/l to 28 μmol/l.

**Relationship between dose, serum carbamazepine concentration and diuretic response**

Observations on the relationship between serum carbamazepine levels, dose and fraction of the water load excreted were extended to include 36 patients. There was no significant relationship between the magnitude of the diuretic response and the prescribed daily carbamazepine dose expressed per unit of body weight (r=-0·23, p>0·05). However, when log-serum carbamazepine concentration values were plotted against diuretic response, a significant negative correlation was found (r=-0·44, p<0·01). Impairment in the ability to excrete a water load was particularly common at serum carbamazepine levels above 28 μmol/l. Although the correlation between diuretic response and serum carbamazepine concentration was stronger in patients treated with carbamazepine alone (r=-0·62 vs -0·36), neither the slope nor the intercept of the regression line were significantly different in patients on a single drug, compared with patients receiving phenytoin in combination.

**Serum carbamazepine concentration in patients treated with carbamazepine alone and in combination with phenytoin**

The observation that patients receiving phenytoin in combination had lower serum carbamazepine levels than patients treated with carbamazepine...
Our original hypothesis that phenytoin may antagonise the antidiuretic effect of carbamazepine was confirmed by the finding that the diuretic response in patients receiving phenytoin in combination was twice as high as in patients receiving equivalent doses of carbamazepine alone. Our data suggest that the difference could be entirely accounted for by a decrease in serum carbamazepine levels during phenytoin therapy. A lowering effect of phenytoin (and phenobarbitone) on serum carbamazepine levels has been described previously by Christiansen and Dam in a comparative study of two different groups of patients, and by Cereghino et al in a within-patient controlled trial. In both of these studies, the magnitude of the effect was remarkably similar to that observed by us. It is of interest that, in our own study, acute administration of phenytoin, 1100 mg over a period of 24 hr, was sufficient to produce a small but significant decrease of the serum carbamazepine concentration in six out of seven subjects. Such an immediate effect appears to be more consistent with an interaction at the absorption site than with induction of carbamazepine metabolism by phenytoin, as generally assumed. On the other hand, induction of carbamazepine metabolism by phenytoin and phenobarbitone is strongly suggested by the shorter carbamazepine half-life and the increased ratio of carbamazepine-10, 11-epoxide to parent drug in the serum of the same patients. Although the epoxide may share some of the pharmacological properties of the parent drug, its accumulation in serum during phenytoin therapy does not appear to compensate to a very important degree for the observed reduction in antidiuretic effect.

The suggestion that phenytoin might antagonise the antidiuretic action of carbamazepine through a pharmacodynamic interaction—for example by inhibiting ADH release from the pituitary—is not supported by our findings. Acute administration of phenytoin did not consistently reverse the antidiuretic effect of carbamazepine; the small increase in diuretic response in some patients following phenytoin intake could have been accounted for entirely by the slight fall in serum carbamazepine concentration which was seen in the same patients after acute phenytoin administration. Lack of pharmacodynamic interaction between carbamazepine and phenytoin is further suggested by the observation that in patients with equivalent serum carbamazepine levels, the diuretic response is impaired to a similar degree whether phenytoin was present or not. Moreover, phenytoin did not appear to influence the regres-

Discussion

This study confirms that carbamazepine treatment may result in an impaired ability to excrete a water load and demonstrates a clear relationship between the magnitude of this effect and the concentration of carbamazepine in serum. A negative correlation between plasma sodium, osmolality and serum carbamazepine concentration has been described before in patients with epilepsy and trigeminal neuralgia.

---

**Fig 3** Serum carbamazepine concentration in 44 epileptic patients treated with carbamazepine, alone (CBZ) or in combination with phenytoin (CBZ + DPH). Patients were paired according to carbamazepine dose.

---

alone was extended to include a larger number of subjects. Twenty-two patients receiving single drug therapy were paired with a corresponding number of patients treated with identical doses of carbamazepine in combination with phenytoin. As illustrated in fig 3, in 21 out of 22 pairs carbamazepine levels measured in fasting serum samples were higher when carbamazepine was used as single drug (p<0.01). In patients treated with carbamazepine alone, serum carbamazepine levels were on average 50% higher than in patients receiving combination therapy (mean ± SD values 33 ± 8 vs 22 ± 6 μmol/l respectively), in remarkably good agreement with the findings obtained by comparison of a smaller number of subjects.
sion line relating serum carbamazepine concentration to antidiuretic effect.

The lack of a pharmacodynamic interaction between phenytoin and carbamazepine may provide indirect evidence on the mechanism of action of the latter drug. Fichman, Bethune and Kleeman have proposed that intravenous administration of phenytoin be used as a diagnostic test to distinguish the syndromes of inappropriate secretion of ADH of non-tumorous etiology (reversed by phenytoin) from those resulting from tumorous production of ADH, or from increased renal responsiveness to the hormone. Our data suggest that carbamazepine-induced antidiuresis is mediated by the last mechanism, at least in patients with normal plasma sodium and osmolality. However, our evidence cannot be regarded as conclusive because phenytoin was given orally and it has been questioned whether the drug is effective in inhibiting ADH release when this route of administration is used. Moreover, we cannot exclude the possibility of carbamazepine having a dual site of action, at both a renal and hypothalamic level, as recently proposed. In conclusion, our data indicate that patients treated with therapeutic doses of carbamazepine and phenytoin in combination show significantly less impairment of water clearance than patients on carbamazepine levels during phenytoin therapy. As phenobarbitone has a similar effect on serum carbamazepine levels it is likely to influence diuretic response in a similar way. Since the reduction in carbamazepine levels is quite marked, the risk of developing water intoxication is likely to be substantially less in patients on combination therapy than in patients receiving carbamazepine alone and clinical evidence supports this conclusion. The risk of water intoxication with carbamazepine as sole drug treatment may be particularly high if adjustments in dosage are made without the assistance of drug levels monitoring. The prescribed dose of carbamazepine has little or no predictive value in assessing the degree of antidiuretic effect, whereas the serum concentration provides a good indication. We suggest, therefore, that serum levels should be monitored routinely when carbamazepine is used alone and that patients stabilised on combination therapy with carbamazepine and phenytoin or other enzyme-inducing drugs should be watched carefully when the latter agents are discontinued or their dosage is reduced.

We thank the Medical Research Council for financial support, and Dr Jolyon Oxley, Senior Physician at the National Hospitals Chalfont Centre for Epilepsy, for allowing us to study patients under his care.

References

15. Eichelbaum M, Köthe KD, Hoffmann F, Von...

